



Europäisches
Patentamt
European
Patent Office
Office européen
des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 19 76 84 00

Classification of the application (IPC):

C07K 14/575, C07K 14/585, C07K 14/47, C07K 7/06, A61K 9/00, A61K 9/06,
A61K 38/16, A61K 47/42, C12P 21/02

Technical fields searched (IPC):

C07K, A61K, C12P

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X A	ELGERSMA RONALD C. ET AL: "Synthesis and structural investigations of N-alkylated [beta]-peptidosulfonamide-peptide hybrids of the amyloidogenic amylin(20-29) sequence: implications of supramolecular folding for the design of peptide-based bionanomaterials" <i>ORGANIC & BIOMOLECULAR CHEMISTRY</i> , 01 January 2006 (2006-01-01), vol. 4, no. 19, DOI: 10.1039/B606875H, ISSN: 1477-0520, pages 3587-3597, XP055866902 * abstract * * page 3588, left-hand column, paragraphs 1,2 * * page 3589, right-hand column, paragraph 1 - page 3593, right-hand column, paragraph 2 *	5, 6 1-4, 7-13, 15
X A	US 2005261179 A1 (CUTTITTA FRANK [US] ET AL) 24 November 2005 (2005-11-24) * sequence 3 *	5, 6 1-4, 7-13, 15
X A	US 5958877 A (WIMALAWANSA SUNIL J [US]) 28 September 1999 (1999-09-28) * sequence 1 *	5, 6 1-4, 7-13, 15
X A	US 5998367 A (GAETA LAURA S L [US] ET AL) 07 December 1999 (1999-12-07) * sequence 9 *	5, 6 1-4, 7-13, 15
A	SUTTER ET AL: "Recombinant gelatin hydrogels for the sustained release of proteins" <i>JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL</i> , 22 May 2007 (2007-05-22), vol. 119, no. 3, DOI: 10.1016/J.JCONREL.2007.03.003, ISSN: 0168-3659, pages 301-312, XP022087330 * abstract * * page 302, left-hand column, paragraph 3 - right-hand column, paragraph 1 * * page 303, right-hand column, paragraph 4 * * page 310, right-hand column, paragraphs 2,3 *	1-13, 15

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search Munich	Date of completion of the search 29 November 2021	Examiner Tudor, Mark
---------------------------	--	-------------------------

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 19 76 84 00

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-13, 15(all partially)

An aqueous pharmaceutical composition for sustained release of therapeutic ingredients, comprising: a self assembling gel-forming polypeptide at a concentration of at least about 0.01 % by weight relative to the total weight of the composition (w/w), and an aqueous excipient, wherein said self-assembling gel forming polypeptide is a G protein-coupled receptor (GPCR) polypeptide ligand selected from amylin, CGRP, adrenomedullin (ADM), and adrenomedullin 2 (ADM2); and subject-matter related thereto.

2. claims: 1-15(partially)

Idem as invention 1, but wherein said the self-assembling gel forming polypeptide is oxytocin, kisspeptin, a kappa opioid receptor agonist, Pralmorelin, a Romiplostim analog, urocortin 3, compstatin, GLP-1, GLP-2, thymosin alpha 1, thymosin beta 4, gamma-MSH, a bombesin receptor antagonist, an opioid receptor ligand, or GnRH, respectively; and subject-matter related thereto.

None of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the first mentioned in the claims, namely claims: 1-13, 15(all partially)

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search Munich	Date of completion of the search 29 November 2021	Examiner Tudor, Mark
---------------------------	--	-------------------------

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



ANNEX TO SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 19 76 84 00

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 29-11-2021
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 2005261179	A1	24-11-2005	AU 2003282660 A1	04-05-2004
			CA 2501282 A1	22-04-2004
			EP 1545287 A2	29-06-2005
			US 2005261179 A1	24-11-2005
			WO 2004032708 A2	22-04-2004
US 5958877	A	28-09-1999	NONE	
US 5998367	A	07-12-1999	HU 222249 B1	28-05-2003
			US 5686411 A	11-11-1997
			US 5998367 A	07-12-1999
			US 2002187923 A1	12-12-2002
			US 2004038900 A1	26-02-2004